Iovance Biotherapeutics, Inc. · NASDAQ:IOVA
Iovance Biotherapeutics — Technical Presentation (November 2024)
12 slides from Iovance Biotherapeutics's technical presentation, November 2024
Slide 1: Society for Immunotherapy of Cancer SITC 2024
Society for Immunotherapy of Cancer Sitc2024 39" Annual Meeting & Pre-Conference Programs Advance the science, discover breakthroughs and educate the world on cancer immunotherapy. #SITC24
Slide 2: Multimodal single-cell sequencing analysis reveals putative tumor-reactive population in lifileucel TIL products
Multimodal single-cell sequencing analysis reveals putative tumor-reactive population in lifileucel TIL products Joe Dean1, Theresa Medina2, Amod Sarnaik3, Jason Chesney4, Mike Cusnir5, Joe Yglesias1, Behzad Damirchi1, Mark Ozeck1, Kranthi Kunkalla1, Brian Gastman1, Rana Fiaz1, Giri Sulur1, Hequn Yi
Slide 3: Disclosures
Disclosures • Joe Dean, Joe Yglesias, Behzad Damirchi, Mark Ozeck, Kranthi Kunkalla, Brian Gastman, Rana Fiaz, Giri Sulur, Hequn Yin, Rongsu Qi: Iovance Biotherapeutics • Theresa Medina: BioAtla, Bristol Myers Squibb, Checkmate, Day One Pharmaceutical, Exicure, Iovance Biotherapeutics, Merck, Modern
Slide 4: Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy background
Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy background Tumor Tissue Procurement Cell Therapy Manufacturing Lifileucel Cell Therapy Patient’s tumor removed Iovance proprietary centralized GMP manufacturing process; 22-day Nonmyeloablative (via surgical resection lymphodepletion, lifil
Slide 5: Dataset and methods
Baseline Tumor Digest Dataset and methods • Single-cell (sc) RNA sequencing and sc T-cell receptor (TCR) sequencing • 10x genomics 5’ immune profiling • C-144-01 metastatic melanoma dataseta • Lifileucel, N=27 • Matched tumor digest (CD45 enriched) and lifileucel, N=7 Lifileucel • High-resolution an
Slide 6: NeoTCR8 T-cell proportion in tumor appears to be associated with response
NeoTCR8 T-cell proportion in tumor appears to be associated with response Marker Genes Baseline Tumor scRNA Cluster Baseline Tumor scTCR Clone Group Response by Proportion of TCR Clones PD, progressive disease; R, responder; SD, stable disease; scRNA, single-cell RNA; scTCR, single-cell T-cell recep
Slide 7: NeoTCR8 T-cell proportion in lifileucel appears to be associated with response
NeoTCR8 T-cell proportion in lifileucel appears to be associated with response Tumor Digest Lifileucel NeoTCR8 Cluster in Lifileucel Full sc Lifileucel Dataset Clusters by Response Total Cell Number (x109) NeoTCR8 cluster TCR clones N=3 N=3 N=1 Where NeoTCR8 **** * T Cells Map in Lifileucel * ** ***
Slide 8: Lifileucel manufacturing process shifts phenotype of NeoTCR8 T cells
Lifileucel manufacturing process shifts phenotype of NeoTCR8 T cells • NeoTCR8 T cells expand into the billions in lifileucel Gene Signature Analysis Comparing NeoTCR8 T Cells in Tumor vs Lifileucel • Upon expansion, NeoTCR8 T cells downregulate Exhaustion gene sets Proliferation gene sets exhaustio
Slide 9: Conclusions
Conclusions • Preliminary results suggest the tumor immune infiltrate from patients with SD and PD contains more bystander T cells, while responders have more putative tumor-reactive TIL • The lifileucel manufacturing process shifts the phenotype of putative tumor-reactive TIL from exhausted to prol
Slide 10: Take-home message
Take-home message • The current analysis suggests that the capture, expansion, and reinvigoration of putative tumor-reactive T cells may be important for efficacy of TIL cell therapy and may help guide future development of TIL drug products
Slide 11: Acknowledgments
Acknowledgments Iovance • Joe Yglesias, Behzad Damirchi, Mark Ozeck, Kranthi Kunkalla, Rana Fiaz, Giri Sulur, Hequn Yin, Rongsu Qi Academic collaborators • Theresa Medina, Amod Sarnaik, Jason Chesney, Mike Cusnir Special thank you to the C-144-01 study patients and their families
Slide 12: Q&A
Q&A @ _, Society for Immunotherapy of Cancer S Itc 39" Annual Meeting & Pre-Conference Programs
Iovance Biotherapeutics — Technical Presentation (November 2024) on 6ix